UNASSIGNED: OBJECTIVE Advances in neuroimaging techniques have led to the increased detection of asymptomatic @entity1653 ( @entity1653 ). Despite several studies on the natural history of @entity1653 , a comprehensive evaluation method for estimating the growth potential of these @entity5 , based on the relative weight of each risk factor, has not been developed. The aim of this study was to develop a weighted scoring system that estimates the risk of rapid @entity5 growth to aid treatment decision making. METHODS The authors performed a retrospective analysis of 232 @entity1 with presumed IM who had been prospectively followed up in the absence of treatment from 1997 to 2013. @entity5 volume was measured by imaging at each follow-up visit, and the growth rate was determined by regression analysis. Predictors of rapid @entity5 growth (defined as >=  2 cm(3)/year) were identified using a logistic regression model; each factor was awarded a score based on its own coefficient value. The probability (P) of rapid @entity5 growth was estimated using the following formula: [Formula: see text] RESULTS Fifty-nine @entity5 (25.4%) showed rapid growth. @entity5 size (OR per cm(3) 1.07, p = 0.000), absence of @entity730 (OR 3.87, p = 0.004), @entity4 (OR 2.74, p = 0.025), and hyperintense or isointense signal on T2-weighted MRI (OR 3.76, p = 0.049) were predictors of @entity5 growth rate. In the Asan @entity1653 Scoring System (AIMSS), @entity5 size was categorized into 3 groups of < 2.5 cm, >=  2.5 to < 4.0 cm, and >=  4.0 cm in diameter and awarded a score of 0, 3, and 6, respectively; the parameters of @entity730 and @entity4 were categorized into 2 groups based on their presence or absence and given a score of 0 or 2 and 1 or 0, respectively; and the signal on T2-weighted MRI was categorized into 2 groups of hypointense and hyperintense/isointense and given a score of 0 or 2, respectively. The risk of rapid @entity5 growth was estimated to be < 10% when the total score was 0-2, 10%-50% when the total score was 3-6, and >=  50% when the total score was 7-11 (Hosmer-Lemeshow goodness-of-fit test, p = 0.9958). The area under the receiver operating characteristic curve was 0.86. CONCLUSIONS The authors suggest a weighted scoring system (AIMSS) that predicts the specific probability of rapid @entity5 growth for @entity1 with untreated IM. This scoring system will aid treatment decision making in clinical settings by screening out @entity1 at high risk for rapid @entity5 growth.

A novel weighted scoring system for estimating the risk of rapid growth in untreated XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors'] @entity4 :: ('MESH:D004487', 'Disease') :: ['peritumoral edema'] @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification'] @entity1653 :: ('MESH:D008579', 'Disease') :: ['intracranial meningiomas', 'Intracranial Meningioma', 'IMs']
@entity1653 :: (MESH:D008579,Disease) :: ['intracranial meningiomas']
